Home › Companies › KINIKSA PHARMACEUTICALS INTERNATIONAL PLC › 2024-2025

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

26Reported items
222Asset managers
3,889Fund votes
2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KINIKSA PHARMACEUTICALS INTERNATIONAL PLC in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

These tallies are KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sanj K. Patel	48,345,527	1,315,700	17,215	--	2,718,179	Majority: yes
Elect Director: Thomas R. Malley	40,767,926	8,874,763	35,753	--	2,718,179	Majority: yes
Elect Director: Richard S. Levy	48,474,904	1,182,085	21,453	--	2,718,179	Majority: yes
Elect Director: Stephen R. Biggar	34,345,226	15,310,717	22,499	--	2,718,179	Majority: yes
Elect Director: G. Bradley Cole	48,537,052	1,118,892	22,498	--	2,718,179	Majority: yes
Elect Director: Barry D. Quart	48,477,460	1,179,591	21,391	--	2,718,179	Majority: yes
Elect Director: Felix J. Baker, Ph.D.	37,399,001	12,262,083	17,358	--	2,718,179	Majority: yes
Elect Director: M. Cantey Boyd	49,525,094	131,795	21,553	--	2,718,179	Majority: yes
Elect Director: Tracey L. McCain	48,523,788	1,119,195	35,459	--	2,718,179	Majority: yes
Elect Director: Kimberly J. Popovits	48,444,882	1,212,399	21,161	--	2,718,179	Majority: yes
Proposal 4: To approve the appointment of PricewaterhouseCoopers LLP (" PwC ") as the Company's UK statutory auditors until the close of the Company's next Annual Meeting.	52,360,413	18,079	18,129	--	0	Majority: yes
Proposal 5: To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2025.	52,359,608	19,322	17,691	--	0	Majority: yes
Proposal 6: To authorize the Company's board of directors, through its audit committee, to determine PwC's remuneration in its capacity as the Company's UK statutory auditors until the close of its next Annual Meeting of Shareholders.	52,357,935	8,139	30,547	--	0	Majority: yes
Proposal 7: To receive the Company's UK statutory annual account and report for the period ended December 31, 2024.	51,839,847	1,442	555,332	--	0	Majority: yes
Proposal 8: To approve, on an advisory non-binding basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2024.	49,232,977	427,203	18,262	--	2,718,179	Majority: yes
Proposal 9: To approve the Company's UK Statutory Directors' Remuneration Policy.	49,456,271	199,712	22,459	--	2,718,179	Majority: yes
Proposal 10: To approve, on an advisory non-binding basis, the compensation of the Company's named executive officers.	49,107,201	550,666	20,575	--	2,718,179	Majority: yes
Proposal 11: To authorize the Company's board of directors to allot shares or convert securities into shares with a total nominal amount capped at $6,976.33, which represents approximately 35% of the Company's issued ordinary share capital on the Record Date.	41,191,486	11,185,289	19,846	--	0	Majority: yes
Proposal 13: To authorize the Company to conduct a transaction with Kiniksa Pharmaceuticals, Ltd., the Company's wholly-owned subsidiary, whereby the Company will redeem preference shares previously issued to it through the capitalization of the Company's merg	52,354,709	23,158	18,754	--	0	Majority: yes

Source: KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, Form 8-K — read the filing on EDGAR.

How asset managers voted at the KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 2024-2025 meeting

Each item below shows how the 222 asset managers that disclosed a KINIKSA PHARMACEUTICALS INTERNATIONAL PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 49,107,201AGAINST: 550,666

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 10: To approve, on an advisory non-binding basis, the compensation of the Company's named executive officers.”): 49,107,201 for, 550,666 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 221 asset managers below cast 99% of the shares they voted on this item FOR (32,224,503 for, 408,465 against).

FOR 99%

FOR: 32,224,503 (98.7%)AGAINST: 408,465 (1.3%)ABSTAIN: 13,261 (0.0%)

Largest asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
BlackRock	3,573,942	6,768	For
Vanguard	3,459,333	0	For
BAKER BROS. ADVISORS LP	2,848,003	0	For
Rubric Capital Management LP	2,523,372	0	For
Fidelity	2,094,680	0	For
Point72	1,481,903	0	For
Fairmount Funds Management LLC	1,396,103	0	For
BRAIDWELL LP	1,267,130	0	For
PICTET ASSET MANAGEMENT SA	1,060,792	0	For
Nuveen	834,042	0	For
TIAA	829,919	0	For
State Street	612,432	367	For
Dimensional	510,361	0	For
GEODE CAPITAL MANAGEMENT, LLC	507,835	0	For
RICE HALL JAMES & ASSOCIATES, LLC	469,487	0	For
Soleus Capital Management, L.P.	464,500	0	For
ArrowMark Colorado Holdings LLC	390,115	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	377,648	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	374,368	0	For
Connor, Clark & Lunn Investment Management Ltd.	363,306	0	For
AQR	339,162	0	For
Charles Schwab	328,744	0	For
Allspring	313,708	0	For
Waddell & Reed	250,569	0	For
DE Shaw	232,793	0	For

Showing the 25 largest of 221 asset managers. See all 221 in the interactive database.

2. TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPANY'S UK STATUTORY DIRECTORS' ANNUAL REMUNERATION REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 49,232,977AGAINST: 427,203

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 8: To approve, on an advisory non-binding basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2024.”): 49,232,977 for, 427,203 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 90 asset managers below cast 99.4% of the shares they voted on this item FOR (17,886,706 for, 90,552 against).

FOR 99.4%

FOR: 17,886,706 (99.5%)AGAINST: 90,552 (0.5%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPANY'S UK STATUTORY DIRECTORS' ANNUAL REMUNERATION REPO” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
BlackRock	3,573,942	6,768	For
Vanguard	3,364,730	0	For
BAKER BROS. ADVISORS LP	2,848,003	0	For
Rubric Capital Management LP	2,523,372	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Soleus Capital Management, L.P.	464,500	0	For
Dimensional	421,009	0	For
Waddell & Reed	250,569	0	For
Granahan Investment Management, LLC	229,194	0	For
Northern Trust	204,653	0	For
Allspring	156,329	0	For
Equitable	106,917	0	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	94,238	0	For
OPTIMUM FUND TRUST	89,812	0	For
CLEARWATER INVESTMENT TRUST	87,156	0	For
PNC BANK, NATIONAL ASSOCIATION	84,669	0	For
Victory Capital	75,469	0	For
ALGERT GLOBAL LLC	70,036	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

3. TO APPROVE THE COMPANY'S UK STATUTORY DIRECTORS' REMUNERATION POLICY.

SHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 49,456,271AGAINST: 199,712

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 9: To approve the Company's UK Statutory Directors' Remuneration Policy.”): 49,456,271 for, 199,712 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 70 asset managers below cast 99.7% of the shares they voted on this item FOR (12,133,649 for, 27,906 against).

FOR 99.6%

FOR: 12,133,649 (99.7%)AGAINST: 27,906 (0.2%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “TO APPROVE THE COMPANY'S UK STATUTORY DIRECTORS' REMUNERATION POLICY.” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
BlackRock	3,573,942	6,768	For
Vanguard	3,364,730	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	421,009	0	For
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	106,917	0	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	94,238	0	For
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
ESSEX INVESTMENT MANAGEMENT CO LLC	83,224	0	For
Victory Capital	75,469	0	For
ALGERT GLOBAL LLC	70,036	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	51,582	0	For
Empower	46,060	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. To authorize the Company's Board of Directors, through its Audit Committee, the authority to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of our next Annual General Meeting of Shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 52,357,935AGAINST: 8,139

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 6: To authorize the Company's board of directors, through its audit committee, to determine PwC's remuneration in its capacity as the Company's UK statutory auditors until the close of its next Annual Meeting of”): 52,357,935 for, 8,139 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 67 asset managers below cast 100% of the shares they voted on this item FOR (10,223,572 for, 0 against).

FOR 99.8%

FOR: 10,223,572 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “To authorize the Company's Board of Directors, through its Audit Committee, the authority to determine PwC's r” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	121,378	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

5. To authorize the Board of Directors to conduct a transaction with the Company's wholly-owned subsidiary, Kiniksa Pharmaceuticals, Ltd. ("Kiniksa Bermuda"), whereby the Company will redeem the preference shares previously issued to Kiniksa Bermuda through the capitalization of the Company's merger reserve account and subsequently cancelling the merger reserve bonus share issued as part of such capi

EXTRAORDINARY TRANSACTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 52,354,709AGAINST: 23,158

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 13: To authorize the Company to conduct a transaction with Kiniksa Pharmaceuticals, Ltd., the Company's wholly-owned subsidiary, whereby the Company will redeem preference shares previously issued to it through ”): 52,354,709 for, 23,158 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 67 asset managers below cast 100% of the shares they voted on this item FOR (10,210,374 for, 0 against).

FOR 99.8%

FOR: 10,210,374 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “To authorize the Board of Directors to conduct a transaction with the Company's wholly-owned subsidiary, Kinik” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	121,378	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

6. To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of our next Annual General Meeting of Shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 52,360,413AGAINST: 18,079

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 4: To approve the appointment of PricewaterhouseCoopers LLP (" PwC ") as the Company's UK statutory auditors until the close of the Company's next Annual Meeting.”): 52,360,413 for, 18,079 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (10,210,366 for, 0 against).

FOR 99.8%

FOR: 10,210,366 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until ” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	121,378	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

7. Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Richard S. Levy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,474,904AGAINST: 1,182,085

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Richard S. Levy”): 48,474,904 for, 1,182,085 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,618,066 for, 592,300 against).

FOR 94%

FOR: 9,618,066 (94.1%)AGAINST: 592,300 (5.8%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their ” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

8. Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Sanj K. Patel

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 48,345,527AGAINST: 1,315,700

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Sanj K. Patel”): 48,345,527 for, 1,315,700 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,615,101 for, 595,265 against).

FOR 94%

FOR: 9,615,101 (94.0%)AGAINST: 595,265 (5.8%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their ” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	106,917	0	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	0	56,770	Against
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

9. Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Thomas R. Malley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 40,767,926AGAINST: 8,874,763

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Thomas R. Malley”): 40,767,926 for, 8,874,763 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 83% of the shares they voted on this item FOR (8,452,178 for, 1,758,188 against).

FOR 83%AGAINST 17%

FOR: 8,452,178 (82.7%)AGAINST: 1,758,188 (17.2%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their ” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,357,530	7,200	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	0	250,569	Against
Charles Schwab	164,372	0	For
Allspring	0	156,329	Against
CLEARWATER INVESTMENT TRUST	34,222	87,156	Against
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	0	99,872	Against
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	0	75,469	Against
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	0	64,095	Against
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	28,500	23,082	For
Empower	46,060	0	For
RBB FUND, INC.	0	44,373	Against
Ivy Variable Insurance Portfolios	0	43,442	Against

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

10. Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Barry D. Quart

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,477,460AGAINST: 1,179,591

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Barry D. Quart”): 48,477,460 for, 1,179,591 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,635,960 for, 574,406 against).

FOR 94%

FOR: 9,635,960 (94.3%)AGAINST: 574,406 (5.6%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

11. Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: G. Bradley Cole

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,537,052AGAINST: 1,118,892

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: G. Bradley Cole”): 48,537,052 for, 1,118,892 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,635,960 for, 574,406 against).

FOR 94%

FOR: 9,635,960 (94.3%)AGAINST: 574,406 (5.6%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

12. Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Stephen R. Biggar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%AGAINST 31%

FOR: 34,345,226AGAINST: 15,310,717

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Stephen R. Biggar”): 34,345,226 for, 15,310,717 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 47.8% of the shares they voted on this item FOR (4,877,232 for, 5,333,134 against).

FOR 47.7%AGAINST 52.2%

FOR: 4,877,232 (47.7%)AGAINST: 5,333,134 (52.2%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,357,530	7,200	For
BlackRock	403,283	1,435,017	Against
Fidelity	813,465	489,854	For
TIAA	0	829,919	Against
Dimensional	0	421,009	Against
Waddell & Reed	0	250,569	Against
Charles Schwab	0	164,372	Against
Allspring	0	156,329	Against
CLEARWATER INVESTMENT TRUST	0	121,378	Against
Equitable	0	106,917	Against
DRIEHAUS MUTUAL FUNDS	0	99,872	Against
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	0	89,395	Against
SEI	0	83,493	Against
Victory Capital	0	75,469	Against
DWS	0	67,144	Against
QUANTITATIVE MASTER SERIES LLC	0	64,377	Against
MFS	0	64,095	Against
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	0	52,669	Against
Lincoln Financial	0	51,582	Against
Empower	46,060	0	For
RBB FUND, INC.	0	44,373	Against
Ivy Variable Insurance Portfolios	0	43,442	Against

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

13. Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Felix J. Baker, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%AGAINST 25%

FOR: 37,399,001AGAINST: 12,262,083

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 37,399,001 for, 12,262,083 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 58% of the shares they voted on this item FOR (5,938,303 for, 4,272,063 against).

FOR 58%AGAINST 42%

FOR: 5,938,303 (58.1%)AGAINST: 4,272,063 (41.8%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until thei” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,357,530	7,200	For
BlackRock	403,283	1,435,017	Against
Fidelity	498,631	804,688	Against
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	0	250,569	Against
Charles Schwab	164,372	0	For
Allspring	0	156,329	Against
CLEARWATER INVESTMENT TRUST	34,222	87,156	Against
Equitable	0	106,917	Against
DRIEHAUS MUTUAL FUNDS	0	99,872	Against
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	0	75,469	Against
DWS	0	67,144	Against
QUANTITATIVE MASTER SERIES LLC	0	64,377	Against
MFS	0	64,095	Against
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	28,500	23,082	For
Empower	46,060	0	For
RBB FUND, INC.	0	44,373	Against
Ivy Variable Insurance Portfolios	0	43,442	Against

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

14. Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Kimberly J. Popovits

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,444,882AGAINST: 1,212,399

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 48,444,882 for, 1,212,399 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,635,960 for, 574,406 against).

FOR 94%

FOR: 9,635,960 (94.3%)AGAINST: 574,406 (5.6%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until thei” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

15. Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: M. Cantey Boyd

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 49,525,094AGAINST: 131,795

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: M. Cantey Boyd”): 49,525,094 for, 131,795 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (10,210,366 for, 0 against).

FOR 99.8%

FOR: 10,210,366 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until thei” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	121,378	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

16. Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Tracey L. McCain

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,523,788AGAINST: 1,119,195

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Tracey L. McCain”): 48,523,788 for, 1,119,195 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 94% of the shares they voted on this item FOR (9,635,960 for, 574,406 against).

FOR 94%

FOR: 9,635,960 (94.3%)AGAINST: 574,406 (5.6%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until thei” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,364,730	0	For
BlackRock	1,838,300	0	For
Fidelity	1,303,319	0	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	250,569	0	For
Charles Schwab	164,372	0	For
Allspring	156,329	0	For
CLEARWATER INVESTMENT TRUST	121,378	0	For
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	99,872	0	For
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	75,469	0	For
DWS	67,144	0	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	64,095	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	47,358	4,224	For
Empower	46,060	0	For
RBB FUND, INC.	44,373	0	For
Ivy Variable Insurance Portfolios	43,442	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

17. To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the UK Companies Act 2006 (the "Companies Act") to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the company ("Rights") up to a maximum aggregate nominal amount of $6,976.33, which represents approximately 35% of the issued ordinary share

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%

FOR: 41,191,486AGAINST: 11,185,289

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 11: To authorize the Company's board of directors to allot shares or convert securities into shares with a total nominal amount capped at $6,976.33, which represents approximately 35% of the Company's issued ord”): 41,191,486 for, 11,185,289 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 65 asset managers below cast 77% of the shares they voted on this item FOR (7,863,029 for, 2,352,655 against).

FOR 77%AGAINST 23%

FOR: 7,863,029 (77.0%)AGAINST: 2,352,655 (23.0%)

Largest asset managers voting on “To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the UK Co” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,357,530	7,200	For
BlackRock	1,435,017	403,283	For
Fidelity	1,278,330	24,989	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	0	250,569	Against
Charles Schwab	164,372	0	For
Allspring	0	156,329	Against
CLEARWATER INVESTMENT TRUST	34,222	79,263	Against
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	0	99,872	Against
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
Victory Capital	0	75,469	Against
DWS	0	67,144	Against
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
MFS	0	64,095	Against
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Lincoln Financial	0	51,582	Against
Empower	46,060	0	For
RBB FUND, INC.	0	44,373	Against
Ivy Variable Insurance Portfolios	0	43,442	Against

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

18. To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 52,359,608AGAINST: 19,322

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 5: To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 52,359,608 for, 19,322 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 65 asset managers below cast 100% of the shares they voted on this item FOR (10,202,423 for, 0 against).

FOR 99.8%

FOR: 10,202,423 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fis” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	113,485	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

19. TO RECEIVE THE COMPANY'S UK STATUTORY ANNUAL ACCOUNTS AND REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 51,839,847AGAINST: 1,442

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Proposal 7: To receive the Company's UK statutory annual account and report for the period ended December 31, 2024.”): 51,839,847 for, 1,442 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 65 asset managers below cast 100% of the shares they voted on this item FOR (10,202,423 for, 0 against).

FOR 99.8%

FOR: 10,202,423 (99.9%)ABSTAIN: 13,261 (0.1%)

Largest asset managers voting on “TO RECEIVE THE COMPANY'S UK STATUTORY ANNUAL ACCOUNTS AND REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024.” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Vote
Vanguard	3,364,730	For
BlackRock	1,838,300	For
Fidelity	1,303,319	For
TIAA	829,919	For
Dimensional	421,009	For
Waddell & Reed	250,569	For
Charles Schwab	164,372	For
Allspring	156,329	For
CLEARWATER INVESTMENT TRUST	113,485	For
Equitable	106,917	For
DRIEHAUS MUTUAL FUNDS	99,872	For
Voya	94,238	For
OPTIMUM FUND TRUST	89,812	For
MERIDIAN FUND INC	89,395	For
SEI	83,493	For
Victory Capital	75,469	For
DWS	67,144	For
QUANTITATIVE MASTER SERIES LLC	64,377	For
MFS	64,095	For
Advisors' Inner Circle Fund III	56,770	For
Exchange Place Advisors Trust	52,669	For
Lincoln Financial	51,582	For
Empower	46,060	For
RBB FUND, INC.	44,373	For
Ivy Variable Insurance Portfolios	43,442	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

20. Subject to the passing of Proposal No. 11, to empower the Board of Directors generally pursuant to section 570(1) and section 573 of the Companies Act to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the general authority conferred on them by Proposal No. 11 as if section 561(1) of the Companies Act did not apply to that allotment. This power (a) sha

CAPITAL STRUCTURE

70% fund support · no official result

FOR 70%AGAINST 30%

The 45 asset managers below cast 70% of the shares they voted on this item FOR (5,260,853 for, 2,298,025 against).

FOR: 5,260,853 (69.6%)AGAINST: 2,298,025 (30.4%)

Largest asset managers voting on “Subject to the passing of Proposal No. 11, to empower the Board of Directors generally pursuant to section 570” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,357,530	7,200	For
Fidelity	804,688	498,631	For
TIAA	829,919	0	For
Dimensional	0	421,009	Against
Waddell & Reed	0	250,569	Against
Allspring	0	156,329	Against
Equitable	67,357	39,560	For
DRIEHAUS MUTUAL FUNDS	0	99,872	Against
Voya	0	94,238	Against
OPTIMUM FUND TRUST	89,812	0	For
CLEARWATER INVESTMENT TRUST	0	79,263	Against
Victory Capital	0	75,469	Against
DWS	0	67,144	Against
MFS	0	64,095	Against
Lincoln Financial	0	51,582	Against
Empower	46,060	0	For
RBB FUND, INC.	0	44,373	Against
Ivy Variable Insurance Portfolios	0	43,442	Against
1290 Funds	0	37,602	Against
WisdomTree	32,112	0	For
Northern Trust	0	27,247	Against
Principal Exchange-Traded Funds	0	24,236	Against
Brinker Capital Destinations Trust	0	23,994	Against
American Century	0	20,333	Against
AIG/SunAmerica	0	19,378	Against

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

21. Subject to the passing of Proposal No. 11, to empower the Board of Directors generally pursuant to section 570(1) and section 573 of the Companies Act to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the general authority conferred on them by Proposal No. 11 as if section 561(1) of the Companies Act did not apply to that allotment. This power (a) sha

CAPITAL STRUCTURE

97% fund support · no official result

FOR 97%

The 12 asset managers below cast 97% of the shares they voted on this item FOR (468,023 for, 13,261 against).

FOR: 468,023 (97.2%)AGAINST: 13,261 (2.8%)

Largest asset managers voting on “Subject to the passing of Proposal No. 11, to empower the Board of Directors generally pursuant to section 570” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
Charles Schwab	164,372	0	For
MERIDIAN FUND INC	89,395	0	For
SEI	83,493	0	For
TARGET PORTFOLIO TRUST	36,500	0	For
CLEARWATER INVESTMENT TRUST	34,222	0	For
Prudential/PGIM	28,100	0	For
Global X	22,591	0	For
Brighthouse	0	13,261	Against
New York Life	7,500	0	For
Nationwide	970	0	For
NEW COVENANT FUNDS	801	0	For
Principal	79	0	For

22. THE RESOLUTION, PENDING PROPOSAL NO. 11, GRANTS THE BOARD THE AUTHORITY TO ISSUE EQUITY SECURITIES FOR CASH UNDER SECTIONS 570(1) AND 573 OF THE COMPANIES ACT, BYPASSING THE RESTRICTIONS OF SECTION 561(1). THIS AUTHORITY, WITH A TOTAL ALLOTMENT VALUE CAPPED AT $6,976.33, EXPIRES ON JUNE 2, 2030; HOWEVER, THE BOARD MAY CONTINUE ENTERING INTO ALLOTMENT AGREEMENTS THEREAFTER.

CAPITAL STRUCTURE

76% fund support · no official result

FOR 76%AGAINST 24%

The 12 asset managers below cast 76% of the shares they voted on this item FOR (1,657,214 for, 518,308 against).

FOR: 1,657,214 (76.2%)AGAINST: 518,308 (23.8%)

Largest asset managers voting on “THE RESOLUTION, PENDING PROPOSAL NO. 11, GRANTS THE BOARD THE AUTHORITY TO ISSUE EQUITY SECURITIES FOR CASH UN” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
BlackRock	1,435,017	403,283	For
QUANTITATIVE MASTER SERIES LLC	64,377	0	For
Advisors' Inner Circle Fund III	56,770	0	For
Exchange Place Advisors Trust	52,669	0	For
Harbor Funds II	40,834	0	For
Jackson National	0	35,365	Against
Securian Funds Trust	0	33,991	Against
MASTER INVESTMENT PORTFOLIO	0	30,668	Against
John Hancock	0	13,883	Against
Bridge Builder Trust	7,441	0	For
GPS Funds I	0	1,118	Against
WILSHIRE MUTUAL FUNDS INC	106	0	For

23. Accept Financial Statements and Statutory Reports

CORPORATE GOVERNANCE

38% fund support · no official result

FOR 38%AGAINST 62%

The 3 asset managers below cast 38% of the shares they voted on this item FOR (7,943 for, 13,206 against).

FOR: 7,943 (37.6%)AGAINST: 13,206 (62.4%)

Largest asset managers voting on “Accept Financial Statements and Statutory Reports” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Vote
FORUM FUNDS II	0	13,206	Against
CLEARWATER INVESTMENT TRUST	7,893	0	For
UNIFIED SERIES TRUST	50	0	For

24. Authorise Issue of Equity

CAPITAL STRUCTURE

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 7,943 against).

AGAINST: 7,943 (100.0%)

Largest asset managers voting on “Authorise Issue of Equity” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
CLEARWATER INVESTMENT TRUST	0	7,893	0	0	Against
UNIFIED SERIES TRUST	0	50	0	0	Against

25. Authorise Issue of Equity without Pre-emptive Rights

CAPITAL STRUCTURE

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 7,943 against).

AGAINST: 7,943 (100.0%)

Largest asset managers voting on “Authorise Issue of Equity without Pre-emptive Rights” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
CLEARWATER INVESTMENT TRUST	0	7,893	0	0	Against
UNIFIED SERIES TRUST	0	50	0	0	Against

26. Ratify PricewaterhouseCoopers LLP as Auditors

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 52,360,413AGAINST: 18,079

The 2 asset managers below cast 100% of the shares they voted on this item FOR (7,943 for, 0 against).

FOR 100%

FOR: 7,943 (100.0%)

Largest asset managers voting on “Ratify PricewaterhouseCoopers LLP as Auditors” at KINIKSA PHARMACEUTICALS INTERNATIONAL PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
CLEARWATER INVESTMENT TRUST	7,893	0	0	0	For
UNIFIED SERIES TRUST	50	0	0	0	For

Largest KINIKSA PHARMACEUTICALS INTERNATIONAL PLC shareholders voting in 2024-2025

Ranked by the number of KINIKSA PHARMACEUTICALS INTERNATIONAL PLC shares each manager voted on the most widely held ballot item of the 2024-2025 meeting.

Top KINIKSA PHARMACEUTICALS INTERNATIONAL PLC shareholders by shares voted, 2024-2025
#	Asset manager	Shares voted
1	BlackRock	3,580,710
2	Vanguard	3,459,333
3	BAKER BROS. ADVISORS LP	2,848,003
4	Rubric Capital Management LP	2,523,372
5	Fidelity	2,094,680
6	Point72	1,481,903
7	Fairmount Funds Management LLC	1,396,103
8	BRAIDWELL LP	1,267,130
9	PICTET ASSET MANAGEMENT SA	1,060,792
10	Nuveen	834,042

Shown as share counts, not percentages: no shares-outstanding figure has been matched to KINIKSA PHARMACEUTICALS INTERNATIONAL PLC for the 2024-2025 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At KINIKSA PHARMACEUTICALS INTERNATIONAL PLC's shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 222 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,889 separate fund positions. Their filings are grouped here into 26 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of our named executive… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KINIKSA PHARMACEUTICALS INTERNATIONAL PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.